Leen Kawas

Leen Kawas | Entrepreneur, Inventor, Innovator and Leader | Managing General Partner at Propel Bio Partners. Hybrid work, especially what I am witnessing within biotech and biopharma, is helping bring opportunities to the companies that endorse it. Whether it’s the post-Covid arrival of the blended workplace, the emergence of the…

The rapidly growing biotechnology sector includes companies focused on producing life-saving drugs and other medical treatments. Funding and logistical obstacles cause some biotech firms to close up shop before they can make significant progress. In contrast, Seattle-based Athira Pharma, Inc. has notably survived these headwinds and is progressing forward. To…

Talking Biotech Podcast 383 Inspiring Innovations; State of Alzheimer’s Therapies Dr. Leen Kawas For a full transcription of this podcast, please see below: [00:00:00] Kevin Folta: Hi everybody, and welcome to this week’s Talking Biotech podcast by Colabra, and this week has really broken down into two different sections. In…

Listen to the full podcast here. Mike: Hello, everyone. I’m Mike Ward, and welcome to Conversations in Healthcare, a series of interviews with industry leaders, brought to you by DRG, part of Clarivate. While many of the conversations that we’ve had in recent times have focused on the impact of…

Recently, I was accepted into the Forbes Business Council, which I consider a significant achievement and an opportunity to grow as a professional and entrepreneur. The Council is renowned as an invite-only group that brings together business leaders to share their experiences with one another and help encourage networking and…

I’ve been thinking a lot about what it means to parent children in this unique time that we’re in, especially in households like mine where both parents work. It takes a lot of communication, determination, and negotiation to be able to maneuver things into a manageable workflow that supports healthy…

Summary Leen Kawas was ousted as Athira’s CEO on October 21, 2021 over an allegation regarding altered images in her PhD research on Dihexa. It is a common misconception that this allegation is unrelated to Athira’s ongoing programs. In fact, Dihexa (aka Fosgo-AM) is the active drug of Fosgonimeton (ATH-1017), and…

Leen Kawas, the Seattle biotech exec who resigned as CEO of Athira Pharma after an investigation found she had altered doctoral research images that helped to form the initial basis for the company, re-emerged Friday as co-founder and managing general partner of a new investment firm called Propel Bio Partners…